Comparative persistence of anti-tumor necrosis factor therapy in ankylosing spondylitis patients : a multicenter international study

Acurcio, Francisco de Assis and Guerra Júnior, Augusto Afonso and da Silva, Michael Ruberson Ribeiro and Gonçalves Pereira, Ramon and Godman, Brian and Bennie, Marion and Nedjar, Hacene and Rahme, Elham (2020) Comparative persistence of anti-tumor necrosis factor therapy in ankylosing spondylitis patients : a multicenter international study. Current Medical Research and Opinion, 36 (4). pp. 677-686. ISSN 0300-7995

[img] Text (Acurcio-etal-CMRO-2020-Comparative-persistence-of-anti-tumor-necrosis-factor-therapy)
Acurcio_etal_CMRO_2020_Comparative_persistence_of_anti_tumor_necrosis_factor_therapy.pdf
Accepted Author Manuscript
Restricted to Repository staff only until 11 February 2021.

Download (844kB) | Request a copy from the Strathclyde author

    Abstract

    Objective. To evaluate persistence on conventional DMARDs (cDMARDs) and anti-TNF therapies, and to identify potential determinants of discontinuation among individuals with ankylosing spondylitis(AS) living in Brazil and Quebec, Canada. Methods. We conducted a cohort study of AS patients using health administrative data (2010-2015). One-year and 2-year persistence rates were assessed. Cox regression was used to identify potential determinants of therapy discontinuation. Results. One-year persistence was less likely in Brazil for both anti-TNF and cDMARDs (Brazil: 62.1% and 30.7%, Quebec: 66.9% and 67.0%). The 2-year persistence rates were lower for both anti-TNF and cDMARD, but remained higher in Quebec (Brazil: 47.9% and 18.1%, Quebec: 51.5% and 53.5%). In multivariate Cox regression analysis, age, sex and comorbidities were associated with persistence in both countries. In Quebec, persistence did not differ between rural and urban regions or with socioeconomic status. While in Brazil, patients in regions with higher Human Development Index and those in cities with lower Gini index were less likely to discontinue therapy. Conclusions. Canadian AS patients were more likely to persist on therapy compared to Brazilian patients, although rates were lower at 2 years in both countries. Socioeconomic disparity in persistence was found in Brazil, but not in Quebec.